Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial.

Dash AS, Hind K, Hans D, Nieves J, Cosman F

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA20 Sept 2025

PMID40974403DOI10.1007/s00198-025-07696-7PepBankPUB-40974403

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide alone increased TBS by 1.1% versus baseline at 18 months, without statistical significance.
In plain wordsIn women with osteoporosis, teriparatide alone did not significantly improve bone texture versus baseline at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeStandard-regimen TBS at 18 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
TBS change
1.1%
standard regimen at 18 months
Source sentences
Summary
In the standard group, TBS increased by 1.1% at 18 months (p = 0.11 vs baseline) and 1.6% at 36 months (p < 0.11 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
Report a problemFND-4097440301

Studies that did not test the peptide alone7

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, TBS increments did not differ between cyclic and standard teriparatide-denosumab regimens at 18 months.
In plain wordsIn women with osteoporosis, bone texture changes did not differ between cyclic and standard teriparatide-denosumab regimens at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTBS increment at 18 months
Study
n = 50
Comparator
Standard sequential regimen
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, there were no group differences in TBS increments at either 18 or 36 months.
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440305
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, TBS increments did not differ between cyclic and standard teriparatide-denosumab regimens at 36 months.
In plain wordsIn women with osteoporosis, bone texture changes did not differ between cyclic and standard teriparatide-denosumab regimens at 36 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTBS increment at 36 months
Study
n = 50
Comparator
Standard sequential regimen
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, there were no group differences in TBS increments at either 18 or 36 months.
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440306
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women receiving teriparatide-denosumab regimens, 17 participants improved their TBS category and 4 deteriorated at 36 months.
In plain wordsIn women receiving teriparatide-denosumab regimens, bone texture categories improved in 17 participants and deteriorated in 4.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedTBS category transitions
Study
n = 50
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Participants with TBS category improvement
17 participants
36 months, both groups
Participants with TBS category deterioration
4 participants
36 months, both groups
Source sentences
Summary
At 36 months, 17 total participants had improvement in their TBS category from either degraded to partially degraded or partially degraded to normal, or degraded to normal with 4 deteriorations to a lower category.
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440307
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, TBS category changes did not differ between cyclic and standard teriparatide-denosumab regimens.
In plain wordsIn women with osteoporosis, bone texture category changes did not differ between cyclic and standard teriparatide-denosumab regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTBS category change between regimens
Study
n = 50
Comparator
Standard sequential regimen
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There was no difference between groups in the TBS category change.
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440308
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, TBS rose 1.6% from baseline at 36 months with standard sequential teriparatide and denosumab, but the reported p value was < 0.11.
In plain wordsIn women with osteoporosis, bone texture rose 1.6% from baseline at 36 months with teriparatide then denosumab, but the reported p value was below 0.11.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedStandard-regimen TBS at 36 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
TBS change
1.6%
standard regimen at 36 months
Source sentences
Summary
In the standard group, TBS increased by 1.1% at 18 months (p = 0.11 vs baseline) and 1.6% at 36 months (p < 0.11 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440302
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, cyclic teriparatide and denosumab increased TBS by 2.4% at 18 months versus baseline.
In plain wordsIn women with osteoporosis, cyclic teriparatide and denosumab improved bone texture at 18 months versus baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic-regimen TBS at 18 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
TBS change
2.4%
cyclic regimen at 18 months
Source sentences
Summary
In the cyclic group, TBS increased by 2.4% and 2.6% at 18 and 36 months from baseline, respectively (both p < 0.05 vs. baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440303
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, cyclic teriparatide and denosumab increased TBS by 2.6% at 36 months versus baseline.
In plain wordsIn women with osteoporosis, cyclic teriparatide and denosumab improved bone texture at 36 months versus baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic-regimen TBS at 36 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
TBS change
2.6%
cyclic regimen at 36 months
Source sentences
Summary
In the cyclic group, TBS increased by 2.4% and 2.6% at 18 and 36 months from baseline, respectively (both p < 0.05 vs. baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32).
Summary · context
DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4097440304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.